Literature DB >> 35416711

Increased blaKPC Copy Number and OmpK35 and OmpK36 Porins Disruption Mediated Resistance to Imipenem/Relebactam and Meropenem/Vaborbactam in a KPC-Producing Klebsiella pneumoniae Clinical Isolate.

Paolo Gaibani1, Gabriele Bianco2, Stefano Amadesi1, Matteo Boattini2, Simone Ambretti1, Cristina Costa2,3.   

Abstract

Herein, we report the in vivo evolution of imipenem/relebactam-resistance in KPC-producing K. pneumoniae (KPC-Kp) isolated from a critically-ill patient treated with multiple combination therapies based on ceftazidime-avibactam or meropenem-vaborbactam. Imipenem/relebactam-resistance was associated to meropenem-vaborbactam cross-resistance and was due to truncated OmpK35 and OmpK36 porins and increased copy of blaKPC copy number. Genome analysis demonstrated that imipenem/relebactam-resistant KPC-Kp harbored a second copy of blaKPC-carrying Tn4401 in a ColRNAI plasmid as a consequence of a transposition event.

Entities:  

Keywords:  Tn4401; copy number; cross-resistance; public health; transposition mechanisms

Mesh：

Substances：

Year:  2022        PMID： 35416711      PMCID： PMC9112950          DOI： 10.1128/aac.00191-22

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.938


  10 in total

1.  Pneumonia and Renal Replacement Therapy Are Risk Factors for Ceftazidime-Avibactam Treatment Failures and Resistance among Patients with Carbapenem-Resistant Enterobacteriaceae Infections.

Authors:  Ryan K Shields; M Hong Nguyen; Liang Chen; Ellen G Press; Barry N Kreiswirth; Cornelius J Clancy
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

2.  Effect of Porins and blaKPC Expression on Activity of Imipenem with Relebactam in Klebsiella pneumoniae: Can Antibiotic Combinations Overcome Resistance?

Authors:  Gregory Balabanian; Michael Rose; Nyla Manning; David Landman; John Quale
Journal:  Microb Drug Resist       Date:  2018-05-21       Impact factor: 3.431

3.  Activity of Imipenem with Relebactam against Gram-Negative Pathogens from New York City.

Authors:  Amabel Lapuebla; Marie Abdallah; Olawole Olafisoye; Christopher Cortes; Carl Urban; David Landman; John Quale
Journal:  Antimicrob Agents Chemother       Date:  2015-05-26       Impact factor: 5.191

4.  In vitro activity of imipenem-relebactam against KPC-producing Klebsiella pneumoniae resistant to ceftazidime-avibactam and/or meropenem-vaborbactam.

Authors:  Donatella Lombardo; Simone Ambretti; Tiziana Lazzarotto; Paolo Gaibani
Journal:  Clin Microbiol Infect       Date:  2022-02-03       Impact factor: 8.067

5.  Identification of mutations in laboratory-evolved microbes from next-generation sequencing data using breseq.

Authors:  Daniel E Deatherage; Jeffrey E Barrick
Journal:  Methods Mol Biol       Date:  2014

6.  Impact of Ceftazidime-Avibactam Treatment in the Emergence of Novel KPC Variants in the ST307-Klebsiella pneumoniae High-Risk Clone and Consequences for Their Routine Detection.

Authors:  Marta Hernández-García; Juan Antonio Castillo-Polo; Desirèe Gijón Cordero; Blanca Pérez-Viso; María García-Castillo; Javier Saez de la Fuente; María Isabel Morosini; Rafael Cantón; Patricia Ruiz-Garbajosa
Journal:  J Clin Microbiol       Date:  2022-03-16       Impact factor: 11.677

7.  Prognostic Utility of the New Definition of Difficult-to-Treat Resistance Among Patients With Gram-Negative Bloodstream Infections.

Authors:  Maddalena Giannella; Linda Bussini; Renato Pascale; Michele Bartoletti; Matteo Malagrinò; Livia Pancaldi; Alice Toschi; Giuseppe Ferraro; Lorenzo Marconi; Simone Ambretti; Russell Lewis; Pierluigi Viale
Journal:  Open Forum Infect Dis       Date:  2019-12-12       Impact factor: 3.835

Review 8.  The role of new carbapenem combinations in the treatment of multidrug-resistant Gram-negative infections.

Authors:  Emilio Bouza
Journal:  J Antimicrob Chemother       Date:  2021-11-22       Impact factor: 5.790

9.  Evolutionary Trajectories toward Ceftazidime-Avibactam Resistance in Klebsiella pneumoniae Clinical Isolates.

Authors:  Alessandra Carattoli; Gabriele Arcari; Giulia Bibbolino; Federica Sacco; Dario Tomolillo; Federica Maria Di Lella; Maria Trancassini; Luigi Faino; Mario Venditti; Guido Antonelli; Giammarco Raponi
Journal:  Antimicrob Agents Chemother       Date:  2021-08-02       Impact factor: 5.191

10.  Epidemiology of Meropenem/Vaborbactam Resistance in KPC-Producing Klebsiella pneumoniae Causing Bloodstream Infections in Northern Italy, 2018.

Authors:  Paolo Gaibani; Donatella Lombardo; Linda Bussini; Federica Bovo; Beatrice Munari; Maddalena Giannella; Michele Bartoletti; Pierluigi Viale; Tiziana Lazzarotto; Simone Ambretti
Journal:  Antibiotics (Basel)       Date:  2021-05-06
  10 in total
  1 in total

Review 1.  Resistance to Ceftazidime/Avibactam, Meropenem/Vaborbactam and Imipenem/Relebactam in Gram-Negative MDR Bacilli: Molecular Mechanisms and Susceptibility Testing.

Authors:  Paolo Gaibani; Tommaso Giani; Federica Bovo; Donatella Lombardo; Stefano Amadesi; Tiziana Lazzarotto; Marco Coppi; Gian Maria Rossolini; Simone Ambretti
Journal:  Antibiotics (Basel)       Date:  2022-05-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.